Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study

Arnold, M; Rutherford, MJ; Bardot, A; Ferlay, J; Andersson, TML; Myklebust, TÅ; Tervonen, H; Thursfield, V; Ransom, D; Shack, L; Woods, RR; Turner, D; Leonfellner, S; Ryan, S; Saint-Jacques, N; De, P; McClure, C; Ramanakumar, AV; Stuart-Panko, H; Engholm, G; Walsh, PM; Jackson, C; Vernon, S; Morgan, E; Gavin, A; Morrison, DS; Huws, DW; Porter, G; Butler, J; Bryant, H; Currow, DC; Hiom, S; Parkin, DM; Sasieni, P; Lambert, PC; Møller, B; Soerjomataram, I; Bray, F

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study

Arnold, M Rutherford, MJ Bardot, A Ferlay, J Andersson, TML Myklebust, TÅ Tervonen, H Thursfield, V Ransom, D Shack, L Woods, RR Turner, D Leonfellner, S Ryan, S Saint-Jacques, N De, P McClure, C Ramanakumar, AV Stuart-Panko, H Engholm, G Walsh, PM Jackson, C Vernon, S Morgan, E Gavin, A Morrison, DS Huws, DW Porter, G Butler, J Bryant, H Currow, DC

Hiom, S Parkin, DM Sasieni, P Lambert, PC Møller, B Soerjomataram, I Bray, F

Permalink

Publication Type:: Journal Article
Citation:: The Lancet Oncology, 2019, 20 (11), pp. 1493 - 1505
Issue Date:: 2019-11-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published VersionAdobe PDF (1.07 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Arnold, M	en_US
dc.contributor.author	Rutherford, MJ	en_US
dc.contributor.author	Bardot, A	en_US
dc.contributor.author	Ferlay, J	en_US
dc.contributor.author	Andersson, TML	en_US
dc.contributor.author	Myklebust, TÅ	en_US
dc.contributor.author	Tervonen, H	en_US
dc.contributor.author	Thursfield, V	en_US
dc.contributor.author	Ransom, D	en_US
dc.contributor.author	Shack, L	en_US
dc.contributor.author	Woods, RR	en_US
dc.contributor.author	Turner, D	en_US
dc.contributor.author	Leonfellner, S	en_US
dc.contributor.author	Ryan, S	en_US
dc.contributor.author	Saint-Jacques, N	en_US
dc.contributor.author	De, P	en_US
dc.contributor.author	McClure, C	en_US
dc.contributor.author	Ramanakumar, AV	en_US
dc.contributor.author	Stuart-Panko, H	en_US
dc.contributor.author	Engholm, G	en_US
dc.contributor.author	Walsh, PM	en_US
dc.contributor.author	Jackson, C	en_US
dc.contributor.author	Vernon, S	en_US
dc.contributor.author	Morgan, E	en_US
dc.contributor.author	Gavin, A	en_US
dc.contributor.author	Morrison, DS	en_US
dc.contributor.author	Huws, DW	en_US
dc.contributor.author	Porter, G	en_US
dc.contributor.author	Butler, J	en_US
dc.contributor.author	Bryant, H	en_US
dc.contributor.author	Currow, DC https://orcid.org/0000-0003-1988-1250	en_US
dc.contributor.author	Hiom, S	en_US
dc.contributor.author	Parkin, DM	en_US
dc.contributor.author	Sasieni, P	en_US
dc.contributor.author	Lambert, PC	en_US
dc.contributor.author	Møller, B	en_US
dc.contributor.author	Soerjomataram, I	en_US
dc.contributor.author	Bray, F	en_US
dc.date.available	2019-06-25	en_US
dc.date.issued	2019-11-01	en_US
dc.identifier.citation	The Lancet Oncology, 2019, 20 (11), pp. 1493 - 1505	en_US
dc.identifier.issn	1470-2045	en_US
dc.identifier.uri	http://hdl.handle.net/10453/138900
dc.description.abstract	© 2019 World Health Organization Background: Population-based cancer survival estimates provide valuable insights into the effectiveness of cancer services and can reflect the prospects of cure. As part of the second phase of the International Cancer Benchmarking Partnership (ICBP), the Cancer Survival in High-Income Countries (SURVMARK-2) project aims to provide a comprehensive overview of cancer survival across seven high-income countries and a comparative assessment of corresponding incidence and mortality trends. Methods: In this longitudinal, population-based study, we collected patient-level data on 3·9 million patients with cancer from population-based cancer registries in 21 jurisdictions in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the UK) for seven sites of cancer (oesophagus, stomach, colon, rectum, pancreas, lung, and ovary) diagnosed between 1995 and 2014, and followed up until Dec 31, 2015. We calculated age-standardised net survival at 1 year and 5 years after diagnosis by site, age group, and period of diagnosis. We mapped changes in incidence and mortality to changes in survival to assess progress in cancer control. Findings: In 19 eligible jurisdictions, 3 764 543 cases of cancer were eligible for inclusion in the study. In the 19 included jurisdictions, over 1995–2014, 1-year and 5-year net survival increased in each country across almost all cancer types, with, for example, 5-year rectal cancer survival increasing more than 13 percentage points in Denmark, Ireland, and the UK. For 2010–14, survival was generally higher in Australia, Canada, and Norway than in New Zealand, Denmark, Ireland, and the UK. Over the study period, larger survival improvements were observed for patients younger than 75 years at diagnosis than those aged 75 years and older, and notably for cancers with a poor prognosis (ie, oesophagus, stomach, pancreas, and lung). Progress in cancer control (ie, increased survival, decreased mortality and incidence) over the study period was evident for stomach, colon, lung (in males), and ovarian cancer. Interpretation: The joint evaluation of trends in incidence, mortality, and survival indicated progress in four of the seven studied cancers. Cancer survival continues to increase across high-income countries; however, international disparities persist. While truly valid comparisons require differences in registration practice, classification, and coding to be minimal, stage of disease at diagnosis, timely access to effective treatment, and the extent of comorbidity are likely the main determinants of patient outcomes. Future studies are needed to assess the impact of these factors to further our understanding of international disparities in cancer survival. Funding: Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; National Health Service England; Norwegian Cancer Society; Public Health Agency Northern Ireland, on behalf of the Northern Ireland Cancer Registry; The Scottish Government; Western Australia Department of Health; and Wales Cancer Network.	en_US
dc.relation.ispartof	The Lancet Oncology	en_US
dc.relation.isbasedon	10.1016/S1470-2045(19)30456-5	en_US
dc.rights	info:eu-repo/semantics/openAccess
dc.subject.classification	Oncology & Carcinogenesis	en_US
dc.title	Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study	en_US
dc.type	Journal Article
utslib.citation.volume	11	en_US
utslib.citation.volume	20	en_US
utslib.for	1112 Oncology and Carcinogenesis	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	open_access	*
pubs.issue	11	en_US
pubs.publication-status	Published	en_US
pubs.volume	20	en_US

Abstract:

© 2019 World Health Organization Background: Population-based cancer survival estimates provide valuable insights into the effectiveness of cancer services and can reflect the prospects of cure. As part of the second phase of the International Cancer Benchmarking Partnership (ICBP), the Cancer Survival in High-Income Countries (SURVMARK-2) project aims to provide a comprehensive overview of cancer survival across seven high-income countries and a comparative assessment of corresponding incidence and mortality trends. Methods: In this longitudinal, population-based study, we collected patient-level data on 3·9 million patients with cancer from population-based cancer registries in 21 jurisdictions in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the UK) for seven sites of cancer (oesophagus, stomach, colon, rectum, pancreas, lung, and ovary) diagnosed between 1995 and 2014, and followed up until Dec 31, 2015. We calculated age-standardised net survival at 1 year and 5 years after diagnosis by site, age group, and period of diagnosis. We mapped changes in incidence and mortality to changes in survival to assess progress in cancer control. Findings: In 19 eligible jurisdictions, 3 764 543 cases of cancer were eligible for inclusion in the study. In the 19 included jurisdictions, over 1995–2014, 1-year and 5-year net survival increased in each country across almost all cancer types, with, for example, 5-year rectal cancer survival increasing more than 13 percentage points in Denmark, Ireland, and the UK. For 2010–14, survival was generally higher in Australia, Canada, and Norway than in New Zealand, Denmark, Ireland, and the UK. Over the study period, larger survival improvements were observed for patients younger than 75 years at diagnosis than those aged 75 years and older, and notably for cancers with a poor prognosis (ie, oesophagus, stomach, pancreas, and lung). Progress in cancer control (ie, increased survival, decreased mortality and incidence) over the study period was evident for stomach, colon, lung (in males), and ovarian cancer. Interpretation: The joint evaluation of trends in incidence, mortality, and survival indicated progress in four of the seven studied cancers. Cancer survival continues to increase across high-income countries; however, international disparities persist. While truly valid comparisons require differences in registration practice, classification, and coding to be minimal, stage of disease at diagnosis, timely access to effective treatment, and the extent of comorbidity are likely the main determinants of patient outcomes. Future studies are needed to assess the impact of these factors to further our understanding of international disparities in cancer survival. Funding: Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; National Health Service England; Norwegian Cancer Society; Public Health Agency Northern Ireland, on behalf of the Northern Ireland Cancer Registry; The Scottish Government; Western Australia Department of Health; and Wales Cancer Network.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/138900